Quynh Ho
VP, M&A and Investments @ GSR
Quynh Ho is a seed investor at GSR focused on Blockchain and FinTech. VP M&A and Investments at GSR, global leader in crypto trading and investment. Ex Investment Banker at Houlihan Lokey focusing on Consumer and Fintech M&A across Europe, the US and Asia. University of Bath Undergraduate with a First-Class Honours Degree in Business. Undertook an academic exchange at McIntire School of Commerce, Universityof Virginia. Previously in start ups and investment banking
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Quynh Ho invests in
Stages Quynh Ho invests in
Countries Quynh Ho invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Blockchain 2 (40%)
- FinTech 1 (20%)
- Medical 1 (20%)
- Biopharma 1 (20%)
- Consulting 1 (20%)
Stage
- Seed 2 (40%)
- Post-IPO Equity 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- United Kingdom 2 (40%)
- Singapore 1 (20%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Libeara
|
Libeara is a financial service company that provides tokenization, financial assets, government securities, and savings services. | Venture - Series Unknown / Apr 07, 2026 | |
Lite Strategy
|
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients inmultiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing. | $100M / Post-IPO Equity / Jul 18, 2025 | |
CAP Labs
|
CAP Labs is a stablecoin developer platform that produces various denominations of redeemable stablecoins. | $1.9M / Pre-Seed / Oct 28, 2024 | |
ClearToken
|
ClearToken is a clearing solution for digital assets that reduces counterparty risk and enables wider institutional usage. | $10M / Seed / Mar 13, 2024 | |
Calimero Network
|
Calimero Network is a blockchain infrastructure that helps clients in controlling data. Calimero Network was founded in 2022 and was headquartered in London. | $8.5M / Seed / Jan 23, 2023 |
Co-Investors
About GSR
GSR has nine years of deep crypto market expertise as a market maker, ecosystem partner and active, multi-stage investor. GSR sources and provides spot and non-linear liquidity in digital assets for token issuers, institutional investors, miners, and leading cryptocurrency exchanges. GSR employs over 300 people around the globe, and its tradingtechnology is connected to 60 trading venues, including the world's leading DEXs. We have a culture of approaching complex problems with tenacity and imagination. We build long-term relationships by offering exceptional service, expertise and trading capabilities tailored to the specific needs of our clients.
GSR Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cristian Gil
Co-Founder
|
|||
|
Eva Sanchez
CLO
|
|||
|
Quynh Ho
VP, M&A and Investments
|
|||
Rich Rosenblum
Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Quynh Ho invest in?
Quynh Ho invests primarily in Blockchain, FinTech and Medical startups, most often at Seed and Post-IPO Equity stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Quynh Ho?
Public channels for Quynh Ho include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Quynh Ho last invest?
The most recent investment recorded for Quynh Ho closed in Apr 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
